Biocon Limited is an Indian biopharmaceutical company based in Bangalore, India. The Company manufactures generic active pharmaceutical ingredients (APIs) that are sold in the developed markets of the United States and Europe. It also manufactures biosimilar insulins, which are sold in India as branded formulations and in both bulk and formulation forms. In research [...]
As reported yesterday, Indian companies have started growing and maturing in terms of monetizing their intellectual property. Tata Steel which spends 1.5 % of total revenue in research and development is contemplating to earn money by licensing its intellectual property to other steel companies. At moment, Tata Steel is the world's seventh largest steel [...]
As reported by Mint, Biocon revenue up 16% but profit hit by loss of licensing. Licensing is surely important source of revenue generation. Biocon’s net profit has declined which is due to loss of licensing income from Pfizer, Divestment of Axicorp stake and licensing income from other partners such as Mylan Inc. Biocon and [...]
